Phytochemical treatments target kynurenine pathway induced oxidative stress

K. Parasram

Department of Biology, University of Windsor, Windsor, Canada

ABSTRACT
Objective: The objective of this paper was to link the phytochemical and metabolic research treating quinolinic acid induced oxidative stress in neurodegenerative disorders.

Methods: Quinolinic acid, a metabolite of the kynurenine pathway of tryptophan catabolism, plays a role in the oxidative stress associated with many neurological disorders and is used to simulate disorders such as Parkinson’s disease.

Results: In these models, phytochemicals have been shown to reduce striatal lesion size, reduce inflammation and prevent lipid peroxidation caused by quinolinic acid.

Conclusion: These results suggest that phenolic compounds, a class of phytochemicals, including flavonoids and diarylheptanoids, should be further studied to develop new treatments for oxidative stress related neurological disorders.

Introduction
Neurodegenerative disorders affect hundreds of millions worldwide [1]. Neurological disorders range from depression to autoimmune disorders, such as amyotrophic lateral sclerosis, and while frequently undiagnosed at an early stage, these diseases can quickly progress into restriction of movement, cognition and altered emotional state [2]. Causes of neurological disorders include alteration in metabolic pathways, protein structure, or physical damage to the brain [3]. Current therapies for neurological disorders have limited effectiveness and drive alternative approaches – such as neuroprotective medicine [4,5].

Huntington’s disease, Alzheimer’s disease and many other neurological disorders have been linked to oxidative stress, which refers to damage to the structure of biomolecules due to reactive oxygen species, such as hydrogen peroxide (Table 1) [6–9]. The current treatments for neurodegenerative diseases are primarily symptom-based with few drugs playing preventative roles [4–9]. Phytochemicals, notably phenolic compounds that contain a hydroxyl functional group, are known for their antioxidant, antitumorogenic, and antiviral activities through free-radical scavenging and/or chelating action [10]. This research has quickly expanded using traditional medicine as a guide for novel therapeutics in the treatment of neurological disorders. High throughput analysis techniques such as mass spectrometry, have enabled researchers to profile more plant extracts than ever before, quickly expanding the list of potential lead compounds [11]. The free-radical scavenging ability of phytochemicals is tested using known oxidative agents, such as 3-nitropropionic acid and quinolinic acid, to investigate biological activity in cells [12].

When studying neurological disorders the kynurenine pathway of tryptophan metabolism (Figure 1) is of particular interest since it has been correlated with many neurological disorders, such as depression and epilepsy [13–16]. The oxidative agent quinolinic acid is linked to Huntington’s disease, amyotrophic lateral sclerosis, suicide, aggression and other disorders [2,14,17–20]. The kynurenine pathway, which occurs in most cells of the central nervous system, catalyzes tryptophan into quinolinic acid, an N-acetyl-D-aspartate (NMDA) receptor agonist and precursor of nicotinamide adenine dinucleotide (NAD+), and picolinic acid via kynurenine [2,21]. Tryptophan is also involved in protein synthesis and is a precursor for serotonin [22]. Kynurenines, metabolites of the kynurenine pathway, often have pro and antioxidant properties with the aromatic hydroxyl acting as an electron acceptor [22].

Quinolinic acid, an excitatory kynurenine antagonized by kynurenic acid, is a choline acetyl transferase known to produce neuronal lesions in the cerebrum at low concentrations [17,23]. Quinolinic acid and kynurenic acid form an important balance in maintaining levels of oxidative stress [24]. Quinolinic acid’s neurotoxicity occurs through three methods: increased glutamate signalling, acting as an N-methyl-D-aspartic acid receptor agonist, or lipid peroxidation [19]. Picolinic acid, which is produced from 2-amino-4-carboxymuconic-6-semialdehyde in the presence of picolinic carboxylase instead of spontaneously transforming into quinolinic acid, acts as an endogenous neuroprotective agent by chelating iron, necessary for quinolinic acid to function, or zinc to antagonize quinolinic acid [19,25]. Therefore, the balance of the kynurenine pathway metabolites is necessary to maintain normal brain function.

Since the kynurenine pathway metabolites can become sources of oxidative stress they are implicated in many
neurological diseases. Metabolites, such as quinolinic acid, are commonly used to test for the neuroprotective potential of phytochemicals. This paper will highlight recent research that indicates the potential for the use of phytochemicals as therapeutic neuroprotective agents by examining phytochemicals showing neuroprotective behavior and resistance to quinolinic acid induced oxidative stress. The research articles referenced in this paper were selected for their study of neurological disorders, use of kynurenines to induce oxidative stress, and testing of phytochemicals to treat oxidation-induced damage.

**Phytochemical protection**

In a Parkinson’s cell model, *Olea europaea*, which contains, a phenolic compound called oleuropein, resisted oxidative stress caused by 6-hydroxydopamine and prevented neuronal death showing a decrease in neuronal death, Bax and Bcl-2 as apoptotic markers and superoxide ($p < 0.05$) [26]. Similarly, *Ficus religiosa* extract treated rats showed improved behavior and reduced lipid peroxidation when treated with 6-hydroxydopamine [4]. *Fructus mume* extract, (200 mg/kg oral), decreased p-ERK, astrocyte cell numbers and pro-inflammatory cytokines in the hippocampus by modulating RAGE signalling white matter is promising for the treatment of vascular dementia, as modelled by chronic cerebral hypoperfusion in Wistar rats [27]. Eugenol, found in cloves, was tested in SHSY5Y cells in diabetes and, hyperglycemic, conditions to assess its potential as a treatment for neuro-oxidative problems in diabetic patients [28]. The results show that eugenol treated cells have decreased oxidative markers and increased glutathione (GSH) levels [28].

### Table 1. An overview of neurological disorders focusing on the main affected regions and the link to oxidative stress, increased glutamate levels cause excitotoxicity and may be triggered by quinolinic acid.

| Neurological disease | Symptoms | Affected region | Role of oxidative stress | References |
|----------------------|----------|----------------|-------------------------|------------|
| Amyotrophic Lateral Sclerosis | Progressive muscle weakness leading to paralysis | Central nervous system (brain stem, spine, cortex) – motor neurons | Mutations in superoxide dismutase 1 sensitizing motor neurons to excitotoxicity, lipid peroxidation, damage to astrocytes and microglia, and inflammation | [2,3] |
| Multiple Sclerosis | Muscle weakness, shaking | Loss of myelin sheath in the central nervous system | Inflammation | |
| Huntington’s Disease | Impairment of motor, cognitive, and behavioural function | Central nervous system – cortex, striatum | Inflammation, lipid peroxidation | [3] |
| Parkinson’s Disease | Muscle weakness, resting tremor, postural instability | Substantia nigra – dopaminergic neurons | Interferes with dopamine metabolism; ROS cause neuron death | [3,4] |
| Alzheimer’s Disease | Impaired memory and cognitive functions | Amyloid beta plaques and tau protein accumulation in the central nervous system notably the hippocampus | Involved in toxicity associated with amyloid beta plaques, inflammation response of microglia, and lipid peroxidation | [3,5,6] |

ROS: reactive oxygen species [2–6].

---

**Figure 1.** The kynurenine pathway of tryptophan metabolism. Tryptophan is transported into the brain by the l-amino acid transporter and converted by indole amine dioxygenases (IDO), rate limiting step, into formylkynurenine and then by kynurenine formamidase into kynurenine. Kynurenine can then be either converted into 3-hydroxykynurenine by kynurenine hydroxylase then into 3-hydroxyanthranilic acid. Once 3-hydroxyanthranilic acid is produced it can then be converted to quinolinic acid spontaneously or picolinic acid by picolinic carboxylase. 3-hydroxykynurenine can be converted to xanthurenic acid and kynurenine into kynurenic acid by kynurenine aminotransferases. NP: neuroprotective; NT: neurotoxic [2,6,22,25,38].
Huntington’s Disease is characterized by striatal neuronal degeneration that may be due to the aggregation of mutant huntingtin protein [29]. Oxidative stress is evident in Huntington’s disease in the reduction of Complex II/III activity in the mitochondrial electron transport chain, superoxide dismutase I and glutathione peroxidase [30]. 3-nitropropionic acid causes mitochondrial dysfunction by disrupting oxidative phosphorylation and the electron transport chain due to its inhibition of succinate dehydrogenase and mitochondrial complex III thereby causing a Huntington’s phenotype [30,31]. Embelin, from Embelia ribes, was tested against 3-nitropropionic acid oxidative damage in adult Wistar rats and showed that when embelin, 10 or 20 mg/kg/day oral, was administered with 3-nitropropionic, 15 mg/kg/day intraperitoneal, after 8 days of damage by 3-nitropropionic acid, there was a reversal of striatal neuronal damage, and a decrease in brain lesion area >69% (\( p < 0.001 \)), improved behaviour and decreased oxidative stress [29].

**Phytochemicals and quinolinic acid**

In the kynurenine pathway, the conversion of tryptophan into formylkynurenine is catalyzed by indoleamine 2,3-dioxygenase and is the rate limiting step of the pathway. Consequently, its inhibition imparts significant neuroprotective effects by controlling quinolinic acid production [32]. Ferulic acid, found in wheat bran and rice was shown to inhibit indoleamine 2,3-dioxygenase activity by inhibiting mitogen-activated protein kinase (MAPK) and NFKB signalling in lipopolysaccharide activated microglia [32].

*Boerhaavia diffusa* extract was tested in rat brain homogenates to assess its ability to negate oxidative damage caused by thiobarbituric acid reactive substances including 3-nitropropionic acid and quinolinic acid [12]. This extract decreased the thiobarbituric acid reactive substances and lipid peroxidation while increasing antioxidant, superoxide dismutase and reduced glutathione, concentrations (\( p < 0.05 \)) [12]. *Crascocephalum crepidiodes* hydrophilic extract was shown to inhibit acetylicholinesperase activity and exhibit free-radical scavenging activity (\( p < 0.05 \)) as well as potential for inhibition of lipid peroxidation (\( p > 0.05 \)) [33].

Examination of the neuroprotective potential of *Centella asiatica* or its butanolic, ethyl acetate or dichloromethane extracts inhibited lipid peroxidation and thiol oxidation in the striatum, hippocampus and cerebral cortex (\( p < 0.05 \)) [34]. *Clerodendrum volubile*, a traditional treatment for neurological disorders, was tested to determine its phenolic composition and free-radical scavenging activity. Leaf extracts reduce malondialdehyde oxidase levels, lipid peroxidation and monoamine oxidase activity (\( p < 0.05 \)) showing its potential as a neuroprotectant [35]. The flavonoids catechin and epicatechin found in cocoa were tested in rat striatal slices treated with quinolinic acid restored GSH levels, protecting against oxidative damage [10].

When quinolinic acid was used to induce neuroinflammation in rats, curcumin and curcumin in combination with piperine improved motor performance (grip strength and narrow beam walk) and prevented neurodegeneration in the striatum [36]. Rats on a fatty-acid-rich diet, from fish and olive oil, had reduced oxidative damage in the striatum, normal circling behaviour and increased GABA levels, when microinjected with quinolinic acid [37]. Thus, demonstrating the neuroprotective nature of fatty acid free-radical scavenging activity [37].

**Conclusion**

Oxidative stress of the central nervous system can be caused by metabolites of the kynurenine pathway, such as quinolinic acid, initiating inflammatory responses that are associated with many neurological disorders. Plants are widely used as rich sources of new chemicals for disease treatment due to the biological activity of phenolic compounds, a class of phytochemicals, including flavonoids and diarylheptanoids, often associated with antioxidant and anti-inflammatory activity. This property can be harnessed to treat neurological disorders that are associated with oxidative damage. Further research is required to elucidate the mechanism(s) of action, specifically the interaction between phytochemicals and reactive oxygen species.

**Acknowledgments**

The author would like to thank Vikash Gupta for technical assistance in manuscript preparation.

**Disclosure statement**

No potential conflict of interest was reported by the author.

**Notes on contributor**

*K. Parasram* received graduate education at the University of Windsor and is now focusing on Neuroscience and genetics research.

**References**

[1] World Health Organization. What are neurological disorders? 2016. Available from: http://www.who.int/features/qa/55/en

[2] Lee JM, Tan V, Lovejoy D, et al. Involvement of quinolinic acid in the neuropathogenesis of amyotrophic lateral sclerosis. Neuropharmacology. 2017;112:346–364.

[3] Lovelace MD, Varney B, Sundaram G, et al. Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases. Neuropharmacology. 2017;112:373–388.

[4] Bhangale JO, Acharya SR. Anti-Parkinson activity of petroleum ether extract of *Ficus religiosa* (L.) leaves. Adv Pharmacol Sci. 2016. DOI:10.1155/2016/9436106.

[5] Essa MM, Vijayan RK, Castellano-Gonzalez G, et al. Neuroprotective effect of natural products against Alzheimer’s disease. Neurochem Res. 2012;37:1829–1842.

[6] Guillemín GJ, Brew BJ. Implications of the kynurenine pathway and quinolinic acid in Alzheimer’s disease. Redox Rep. 2002;7:199–206.

[7] Guillemín GJ, Kerr SJ, Brew BJ. Involvement of quinolinic acid in AIDS dementia complex. Neurotox Res. 2005;7:103–123.

[8] Schwarz R, Stone TW. The kynurenine pathway and the brain: challenges, controversies and promises. Neuropharmacology. 2011;51:237–247.

[9] Erhardt S, Schwierl E, Imbeault S, et al. The kynurenine pathway in schizophrenia and bipolar disorder. Neuropharmacology. 2011;51:297–306.

[10] Santamaría-del Ángel D, Labra-Ruíz NA, García-Cruz ME, et al. Comparative effects of catechin, epicatechin and N-ω-nitroarginine on quinolinic acid-induced oxidative stress in rat striatum slices. Biomed Pharmacother. 2016;78:210–215.

[11] Stylos E, Chatziathanasiadou MV, Syriopoulou A, et al. Liquid chromatography coupled with tandem mass spectrometry (LC–MS/MS) based bioavailability determination of the major classes of phytochemicals. J Chromatogr B. 2016. DOI:10.1016/j.jchromb.2016.12.022.
[12] Ayyappan P, Palayyan SR, Kozhiparambil Gopalan R. Attenuation of oxidative damage by Boerhaavia diffusa L. against different neurotoxic agents in rat brain homogenate. J Diet Suppl. 2016;13:300–312.

[13] Heyes MP, Saito K, Crowley JS, et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain. 1992;115:1249–1273.

[14] Savitz J, Drevets WC, Wurfel BE, et al. Reduction of kynurenic acid to quinolinic acid ratio in both the depressed and remitted phases of major depressive disorder. Brain Behav Immun. 2015;46:55–59.

[15] Clark SM, Pociuvasek A, Nicholson JD, et al. Reduced kynurenine pathway metabolism and cytokine expression in the prefrontal cortex of depressed individuals. J Psychiatry Neurosci. 2016;41:386–394.

[16] Boeck CR, Ganzella M, Lottermann A, et al. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science. 1983;219:316–318.

[17] Cho HJ, Savitz J, Dantzer R. Sleep disturbance and kynurenine pathway metabolism in a group of currently depressed, previously depressed, and never depressed subjects. Brain Behav Immun. 2016;57:e14.

[18] Bryleva EY, Brundin L. Kynurenine pathway metabolites and suicidality. Neuropharmacology. 2017;112:324–312.

[19] Clark SM, Pocivavsek A, Nicholson JD, et al. Reduced kynurenine pathway metabolism and cytokine expression in the prefrontal cortex of depressed individuals. J Psychiatry Neurosci. 2016;41:386–394.

[20] Colle D, Santos DB, Hartwig JM, et al. Succinobucol, a lipid-lowering drug, protects against 3-nitropropionic acid-induced mitochondrial dysfunction and oxidative stress in SH-SYSY cells via upregulation of glutathione levels and glutamate cysteine ligase activity. Mol Neurobiol. 2016;53:2619–2635.

[21] Oliveira T, Oshino M, Moroni F. Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites. Eur J Pharmacol. 1999;375:87–100.

[22] Zhuravlev AV, Zakharov GA, Shchegolev BF, et al. Antioxidant properties of kynurenines: density functional theory calculations. PLoS Comput Biol. 2017;12(11):e1005213.

[23] Perkins MN, Stone TW. An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res. 1982;247:184–187.

[24] Nemeth H, Toldi J, Vecsei L. Kynurenines, Parkinson’s disease and other neurodegenerative disorders: preclinical and clinical studies. J Neural Transm. 2006;70:285–304.

[25] Jhamandas KH, Boegman RJ, Beninger RJ, et al. Excitotoxicity of quinolinic acid: modulation by endogenous antagonists. Neurotox Res. 2000;2:139–155.

[26] Achour I, Aré-l-Dubeau AM, Renaud J, et al. Oleuropein prevents neuronal death, mitigates mitochondrial superoxide production and modulates autophagy in a dopaminergic cellular model. Int J Mol Sci. 2016;17:1293–1217.

[27] Kim MS, Bang JH, Lee J, et al. Fructus murome ethanol extract prevents inflammation and normalizes the septohippocampal cholinergic system in a rat model of chronic cerebral hypoperfusion. J Med Food. 2016;19:196–204.

[28] Prasad SN, Bharath MMS, Muralidhara. Neurorestorative effects of eugenol, a spice bioactive: evidence in cell model and its efficacy as an intervention molecule to abrogate brain oxidative dysfunctions in the streptozotocin diabetic rat. Neurochem Int. 2016;95:24–36.

[29] Dhaddé SB, Nagakannan P, Roopesh M, et al. Effect of embelin against 3-nitropropionic acid-induced Huntington’s disease in rats. Biomed Pharmacother. 2016;77:52–58.

[30] Jang M, Cho IH. Sulforaphane ameliorates 3-nitropropionic acid-induced striatal toxicity by activating the Keap1-Nf-κB pathway and inhibiting the MAPKs and NF-κB pathways. Mol Neurobiol. 2016;53:2619–2635.

[31] Koshiguchi M, Komazaki H, Hirai S, et al. Ferulic acid suppresses expression of tryptophan metabolic key enzyme indoleamine 2,3-dioxygenase via NFκB and p38 MAPK in lipopolysaccharide-stimulated microglial cells. Biosci Biotechnol Biochem. 2017;81:1–6.

[32] Oboh G, Ogunruku OO, Oyeleye SI, et al. Chlorogenic acid inhibits cholinergic and monoaminergic functions in the rat brain. J Food Biochem. 2015. DOI:10.1111/jfbc.12200.

[33] Adefegha SA, Oboh G, Molehin OR, et al. Centella asiatica and its fractions reduces lipid peroxidation induced by quinolinic acid and sodium nitroprusside in rat brain regions. Neurochem Res. 2015;40:1197–1210.

[34] Adegbani A, Oboh G, Molehin OR, et al. Centella asiatica and its fractions reduces lipid peroxidation induced by quinolinic acid and sodium nitroprusside in rat brain regions. Neurochem Res. 2015;40:1197–1210.

[35] Oboh G, Ogunruku OO, Oyeleye SI, et al. Phenolic extracts from Clerodendrum volubile leaves inhibit cholinergic and monoaminergic enzymes relevant to the management of some neurodegenerative diseases. J Diet Suppl. 2017;14:358–371.

[36] Singh S. Neuroprotective activity of curcumin in combination with piperine against quinolinic acid-induced neurodegeneration in rats. Alzheimer’s Dement. 2016;12:P621.

[37] Morales-Martínez A, Sánchez-Mendoza A, Martinez-Lazcano JC, et al. Essential fatty acid rich diets protect against striatal oxidative damage induced by quinolinic acid in rats. Nutr Neurosci. 2016. DOI:10.1080/1028415X.2016.1174768.

[38] Schwarz R, Bruno JP, Muchowski PJ, et al. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci. 2012;13(7):465–477.